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Summary
The reticulon family is a large and diverse group of membrane-associated proteins found
throughout the eukaryotic kingdom. All of its members contain a carboxy-terminal reticulon
homology domain that consists of two hydrophobic regions flanking a hydrophilic loop of 60-70
amino acids, but reticulon amino-terminal domains display little or no similarity to each other.
Reticulons principally localize to the endoplasmic reticulum, and there is evidence that they
influence endoplasmic reticulum-Golgi trafficking, vesicle formation and membrane
morphogenesis. However, mammalian reticulons have also been found on the cell surface and
mammalian reticulon 4 expressed on the surface of oligodendrocytes is an inhibitor of axon
growth both in culture and in vivo. There is also growing evidence that reticulons may be
important in neurodegenerative diseases such as Alzheimer’s disease and amyotrophic lateral
sclerosis. The diversity of structure, topology, localization and expression patterns of reticulons
is reflected in their multiple, diverse functions in the cell.
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Gene organization and evolutionary history
Proteins of the reticulon family are present in all eukaryotic
organisms examined and range in size from 200 to 1,200
amino acids. The vertebrate proteins of this family are called
reticulons (RTNs) and those found in other eukaryotes are
called reticulon-like proteins (RTNLs). All family members
contain the reticulon homology domain (RHD), a conserved
region at the carboxy-terminal end of the molecule consis-
ting of two hydrophobic regions flanking a hydrophilic loop.
Reticulons have been identified in the genomes of Homo
sapiens, Mus musculus, Danio rerio, Xenopus laevis, Droso-
phila melanogaster, Caenorhabditis elegans, Arabidopsis
thaliana, Saccharomyces cerevisiae and many other
eukaryotes, but not in archaea or bacteria [1-6]. The ubiquity
of reticulons in the eukaryotic kingdom is consistent with a
highly conserved function and/or a diversity of functions.
Nearly all reticulon genes contain multiple introns and
exons, and most are alternatively spliced into multiple iso-
forms [1]. Intron losses and gains over the course of
evolution have given rise to the large, diverse reticulon
family. The presence of reticulons in eukaryotic but not pro-
karyotic organisms and their close association with the
endoplasmic reticulum (ER) suggest that reticulons evolved
along with the eukaryotic endomembrane system.
Across phyla, the second hydrophobic region of the RHD is
the most highly conserved, followed by the first hydrophobic
region, with the carboxyl terminus the least conserved [7]. In
mammals, there are four reticulon genes encoding reticulon
proteins RTN1-4. The RHDs of RTN1, 3 and 4 share the
highest sequence identity at the amino-acid level (average
73%), whereas RTN2 has only 52% identity with human
RTN4 (Figure 1). The amino-acid sequence identity between
RHDs of C. elegans and S. cerevisiae drops to 15-50%.
In contrast to the highly conserved carboxy-terminal RHD,
the amino-terminal regions of reticulons display no sequence
similarity at all, even among paralogs within the same species
[8]. Furthermore, the expression patterns of differentreticulons and their splice isoforms can be variable, even
within the same organism [9-11]. This divergence in
sequence and expression is consistent with evolution of
species- and cell-type-specific roles for reticulons [12]. This
is particularly clear in the mammalian RTN family, in which
the longest isoform of RTN4, RTN4A, also known as Nogo-A,
has been shown to inhibit neurite outgrowth and axon
regeneration in models of injury [8,13-18]. Interestingly,
RTN4A was found to be absent in fishes, organisms in which
there is extensive regeneration of the CNS after injury [4].
Divergent results for genetic knockouts of different regions
and isoforms of RTN4 suggest that the amino-terminal
domain might contribute to the inhibition of nerve regenera-
tion after injury [12]. Thus, the divergent reticulon amino-
terminal domains appear to carry out species- and cell-
specific roles, whereas the RHD may carry out more basic
cellular functions.
Characteristic structural features
The RHD consists of two hydrophobic regions, each 28-36
amino acids long, which are thought to be membrane-
embedded regions, separated by a hydrophilic loop of 60-70
amino acids, and followed by a carboxy-terminal tail about 50
amino acids long (Figure 2a). Although much amino-acid
identity has been lost over the course of evolution, the overall
structure of the RHD has been preserved from plants to yeasts
to humans. This suggests that three-dimensional protein
structure is of greater importance than individual residues for
RHD function. The RHD hydrophobic regions are unusually
long for transmembrane domains: each spans approximately
30-35 amino acids, whereas most transmembrane domains
are about 20 amino acids in length. This raises the interesting
question of whether this longer length has significance for
reticulon function. The topology of these hydrophobic regions
within membranes is so far only partially defined.
Reticulon topology
The RHD loop region has been detected both on the surface
of cells and intracellularly, and it has been suggested that
the RHD hydrophobic regions might either span the ER
membrane or plasma membrane completely or might
double back on themselves to form a hairpin (Figure 2b).
Antibodies against the amino-terminal domain of RTN4
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Figure 1
Phylogenetic analysis of the reticulon homology domains (RHDs) of selected RTNs and RTNLPs. Alignments were created using the ClustalW2 program
[99] and the tree was generated with Phylo_win software [100]. Bootstrap numbers are shown; the number of repetitions was 1,000. The tree was
generated using the maximum likelihood method. GenBank accession numbers are as follows: H. sapiens RTN1A, NP_066959; H. sapiens RTN2A,
NP_005610; H. sapiens RTN3A, NP_006045; H. sapiens RTN4A, NP_065393; M. musculus RTN1A, NP_703187; M. musculus RTN2B, NP_038676;
M.musculus RTN3A, NP_001003934; M. musculus RTN4A, NP_918943; G. gallus RTN4, NP_989697; X. laevis RTN2A, NP_001089014; X. laevis RTN4,
NP_001083238; D. rerio RTN4, NP_001018620; D. melanogaster Rtnl1A, NP_787987; C. elegans RET-1, NP_506656; S. cerevisiae RTNLA, NP_010077;
A.thaliana RTNLB3, NP_176592.
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47bind to the surface of chick oligodendrocytes in live spinal
cord explants [8] and cultured oligodendrocytes interact
specifically with both amino-terminal domain-specific
antibodies and antibodies directed against the RTN4 66-
amino-acid loop (66-loop) [16]. These findings suggest that
the amino terminus and the 66-loop project into
extracellular space, and therefore that the first RHD
hydrophobic region must double back on itself in the
membrane. However, other data suggest that the amino-
terminal domain is intracellular. Antibodies against the 66-
loop region of RTN4 detect small amounts of this epitope
on the surface of live COS-7 cells, but antibodies against c-
Myc tags fused to either the amino or the carboxy terminus
do not bind to live cells [8].
More recent data from non-neuronal cells in which RTN4 is
overexpressed strongly support a third model, in which most
of both the amino-terminal domain and the 66-loop are
cytoplasmic. In COS cells treated with maleimide polyethylene
glycol, cysteines in the amino-terminal domain and the loop
regions of ER-associated RTN4 were found to be modified
by the reagent after detergent disruption of the plasma
membrane but not the ER membrane [6]. Cysteines in the
carboxy-terminal region were only partially modified. All
these results suggest that mammalian reticulons might have
different topologies in the ER and plasma membranes; such
multiple conformations may enable them to carry out
multiple roles in the cell. Another protein with multiple
membrane topologies is the mammalian prion protein (PrP);
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Figure 2
The structure and membrane topology of reticulons. (a) Structure of reticulon proteins. Numbers refer to the exons that encode the protein regions.
Black ovals represent hydrophobic regions. GenBank accession numbers are as in Figure 1. (b) Possible topologies of reticulon proteins in membranes.
Although eight or more conformations are possible, only those for which evidence exists are depicted. Different topologies in different cell types and
different membranes may enable reticulons to carry out diverse roles in the cell.
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Noverexpression of a certain transmembrane form of the prion
protein,  CtmPrP, causes neurodegenerative disease distinct
from that caused by the natural pathogenic prion form PrPSc
[19,20]. Another possibility is that reticulons assume different
topologies in different cell types: the reticulon amino-terminal
region has been detected only in the cytoplasm in COS-7 cells,
but has been found on both the surface and in the cytoplasm
of oligodendrocytes. Again, this may reflect the diverse roles
of reticulon proteins in different cell types.
Reticulon tertiary structure
The solution structure of the RHD loop of RTN4, known as
Nogo66, has recently been probed by circular dichroism
(CD) and nuclear magnetic resonance (NMR). Nogo66 is
soluble in pure water and consists of three alpha helices, two
short flanking one long, spanning residues 6-15, 21-40 and
45-53, followed by the unstructured residues 55-60 [21,22].
The Nogo66 loop is involved in several RTN4-specific
signaling cascades, including interaction with the Nogo
receptor (NogoR) to inhibit neurite outgrowth [23], and with
the cell adhesion molecule contactin-associated protein
(Caspr) [24] to mediate the localization of potassium
channels at axonal paranodes. The human RTN1 and RTN3
66-loops share 71% and 63% identity with the RTN4 loop;
mouse RTN1 and RTN3 identity with human RTN4 is 67%
and 59%. Despite this high degree of identity, the RTN1
66-loop does not bind to NogoR, and the function of the
66-loops in RTN1 and RTN3 is unknown in both mammals
and lower organisms.
As mentioned above, the amino-terminal regions of different
reticulons are highly divergent in sequence. The amino-
terminal domains of the human RTN4 isoforms appear to be
highly unstructured, even under physiological conditions. In
silico  analysis and measurements by CD and NMR of the
human isoforms RTN4A and RTN4B reveal a high degree of
disorganization, with only short alpha helices and beta
sheets that exist transiently [25]. Recent studies have shown
that intrinsically unstructured proteins (IUPs) are more
likely to form multiprotein complexes than are proteins with
stable tertiary structure [26], are better able to ‘moonlight’ -
carry out alternative functions [25] - and may fold upon
binding to their partners [27]. It has been shown that up to
33% of eukaryotic proteins contain long disordered regions,
compared with 2% of archeal proteins [25]. The characteri-
zation of RTN4 as an intrinsically unstructured/disordered
protein may explain its involvement in many physiological
processes, as explained below.
Localization and function
The first known reticulon protein, RTN1, was identified from
a cDNA in neural tissue [28] and subsequently characterized
as an antigen specific to neuroendocrine cells [29]. This so-
called neuroendocrine-specific protein (NSP) was later
renamed reticulon when it was discovered by both immuno-
histochemical and biochemical methods to be associated with
the ER in COS-1 cells [30]. Reticulons do not contain an ER
localization sequence per se, but a single RHD hydrophobic
region is sufficient to target an enhanced green fluorescent
protein-RTN fusion protein to the ER, whereas deletion of
the RHD abolishes association with the ER [13,31].
Reticulons have been shown to localize to the ER in yeast,
Arabidopsis, C. elegans, Xenopus, Drosophila and mammals
[2,3,5,6,32-34]. Most reticulon research has focused on
RTN4 in the CNS and its effects on neurite outgrowth and
axonal regeneration after spinal cord injury. However, the
presence of reticulons in all eukaryotic organisms and their
ubiquitous ER-associated expression indicate a more general
role. We shall focus on three areas of reticulon localization
and function: ER-associated roles, oligodendrocyte-
associated roles in inhibition of neurite outgrowth, and the
role of reticulons in neurodegenerative diseases.
ER-associated reticulons and their function
There is growing evidence that reticulons are involved in
bending and shaping the ER membrane, in trafficking of
material from the ER to the Golgi apparatus, and in
apoptosis (Figure 3).  Antibody-mediated inhibition of
RTN4A in mammalian cells prevents GTP-induced
formation of elongated membrane tubules in vitro [6], and
knocking out both the C. elegans RTNL RET-1 and its
associated protein YOP-1 interferes with ER formation
during mitosis in the worm [33]. RTN4A also localizes to
subdomains of the Xenopus nuclear envelope, and its
inhibition by anti-RTN4A antibodies limits nuclear envelope
assembly [35]. C. elegans RET-1 also interacts with the
protein RME-1, a regulator of endocytic recycling [36-38]. In
a yeast two-hybrid screen, the mammalian RTN1 isoforms
RTN1A and RTN1B were found to interact with a component
of the mammalian endocytosis adaptor complex AP-2.
RTN1C, in contrast, may be involved in exocytosis. It
associates with calreticulin-negative regions of the ER and
co-immunoprecipitates with the SNARE proteins syntaxin 1,
syntaxin 7, syntaxin 13 and VAMP2 [39]. Overexpression of
a fragment of RTN1C increases the rate of exocytosis in PC12
cells. RTN1, RTN2, and RTN4 were all identified in a yeast
two-hybrid screen using the vesicle fusion protein chaperone
β-SNAP as bait, although these results were not confirmed
by co-immunoprecipitation [40]. In summary, reticulons
interact with proteins involved in vesicular formation and
fusion such as SNAREs and SNAPs. Reticulons also appear
to play a role in ER morphogenesis; nevertheless, cells
lacking reticulon expression do not have major defects in
ER, endosomal or microsomal structure.
Reticulons are also involved in intracellular trafficking - a
close cousin of vesicle formation and recycling. Over-
expression of RTN3 in HeLa cells prevents retrograde
transport of proteins from the Golgi complex to the ER
[41]. In yeast, RTNL1B forms complexes with Yip3p, the
yeast ortholog of the mammalian Rab-GDI displacement
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vesicle trafficking between organelles, and are regulated by
GDFs [42]. In C. elegans, inhibition of RET-1 and YOP-1
disrupted nuclear envelope assembly, and of 29 Rabs
screened, depletion of Rab5 mimicked this phenotype
closely [33]. In a screen in human cells for GTPase-
activating proteins (GAPs), which inhibit Rab function, the
protein TBC1D20 was found to be a GAP for Rab1 and
Rab2, and in the same study, interaction between RTN1C
and TBC1D20 was identified in a yeast two-hybrid screen, a
further argument for a role for reticulons as regulators of
Rab-regulated intracellular trafficking [43].
In mammalian cells, reticulons may also play a role in
apoptosis. Both RTN1C and what is now known to be RTN4A
were identified in a screen for interactors with Bcl-XL, a
powerful inhibitor of apoptosis [44]. RTN1C was found to
inhibit Bcl-XL, and RTN4A was found to inhibit both Bcl-XL
and another apoptosis inhibitor, Bcl-2, demonstrating a pro-
apoptotic role for reticulons. More recently, RTN1C was
shown to modulate apoptosis by upregulating the sensitivity
of the ER to stressors in neuroblastoma cells [45]. Several
labs have shown that RTN3 also enhances apoptosis via
interaction with Bcl-2 [46-48]. Although these and other
data indicate that reticulons may have a role in tumor
suppression via upregulation of apoptosis, this topic is not
without controversy [49].
Oligodendrocyte reticulon and its role in neurite
outgrowth inhibition
The longest isoform of RTN4, RTN4A, has been extensively
characterized in the mammalian CNS (recently reviewed by
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Figure 3
The expression and function of reticulons. (a) Myc-tagged reticulon constructs transfected into COS-7 cells show a reticular expression pattern. Scale
bar, 70 µm. (b) Proteins known to interact with ER-associated and intracellular reticulons and their possible intracellular roles. Some classes of proteins
may overlap in their cellular functions.Liu et al. [50]). It had long been known that in contrast to
the myelin of the peripheral nervous system, myelin from
the CNS appeared to prevent neuronal regeneration after
injury [51]. In 1988, by size fractionation of rat CNS myelin,
Caroni and Schwab discovered a 250 kDa inhibitor of
neurite outgrowth [52]. This protein was later identified as a
novel reticulon (RTN4A) and also named Nogo-A after its
inhibitory effect on neuronal regeneration [8,13,14]. As the
protein is generally called by this name in neuronal
regeneration studies, we shall use that name in the following
discussion. GrandPré et al. [8] showed that the extra-
cellular/ER luminal portion of Nogo-A, the 66-loop termed
Nogo66, is a potent inhibitor of neurite outgrowth. The
receptor for Nogo66 was subsequently identified and termed
NogoR [23]. Inhibition of NogoR using the antagonist
peptide NEP1-40 releases myelin-mediated inhibition of
neurite outgrowth in culture, and both the acute intrathecal
delivery and delayed systemic delivery of NEP1-40 promotes
axonal regeneration of corticospinal tract fibers after dorsal
hemisection in rats [18,53-55]. Work on the amino-terminal
domain of Nogo-A demonstrated its capacity to induce
growth-cone collapse independent of NogoR via a region
now called ∆20 [16,23], whereas another amino-terminal
region, termed Nogo-A-24, is known to enhance the binding
affinity of Nogo66 for NogoR when fused to Nogo66 [15].
Interestingly, the RHD region common to all isoforms of
Nogo (RTN4) is alone sufficient to delay nerve regeneration
after sciatic nerve crush [56].
Numerous in vivo studies in animals have found that either
genetic ablation or pharmacological inhibition of the Nogo-
A-NogoR interaction promotes axon growth and behavioral
recovery after spinal cord injury [17,18,53,54,57-62], and
significant improvement of recovery after similar prevention
of Nogo-A action is also seen after stroke injury [63-65]. The
field is not free from controversy, however [66,67]. The
genetic background can alter the effects of Nogo inhibition
[68], and studies of spinal cord injury in Nogo-knockout
animals generated in different laboratories have yielded
variable results [69-71]. The weight of evidence for a role for
Nogo-A as an inhibitor of neurite outgrowth and a limitor of
axon growth in spinal cord injury, however, make it a prime
target for therapeutic intervention. Indeed, clinical trials of
anti-Nogo antibodies are already under way.
Although the mechanism of action of reticulon in the ER
remains to be elucidated, the mechanism by which Nogo-A
inhibits neurite outgrowth and axon regeneration in the CNS
is well characterized (Figure 4, Table 1). The receptor -
NogoR - for the Nogo66 region was identified in 2001 [21],
but this receptor lacks a transmembrane and signaling
domain and so must interact with a co-receptor or other
signal transducer. Several candidates for this role have been
discovered: the neurotrophin receptor p75, the transmem-
brane protein LINGO-1 and the orphan tumor necrosis
factor family member TAJ/TROY have all been shown to
bind NogoR and participate in the inhibition of neurite
outgrowth  in vitro [72-78] (see Figure 4, Table 1). The
epidermal growth factor receptor (EGFR) may indirectly be
a signal transducer for NogoR - the kinase activity of EGFR
has been shown to be required for the inhibitory action of
Nogo66 in culture - but EGFR does not directly bind NogoR
[78]. A crystal structure of the ligand-binding domain of the
NogoR receptor has been determined [79,80].
NogoR and all its putative co-receptors rely on the small
GTPase RhoA for their downstream effects. Upon RhoA
activation as a result of NogoR signaling, Rho-activated kinase
(ROCK) stimulates actinomyosin activity, causing growth-
cone collapse [50,81]. Blocking Rho activity either pharma-
cologically or with dominant-negative RhoA releases Nogo66-
mediated neurite outgrowth inhibition in vitro [82-85].
Frontiers
Many aspects of our knowledge of the reticulon protein
family remain incomplete. There is no consensus on the
mechanism(s) underlying the ER-associated function of
reticulons, and debate continues over the role of mammalian
Nogo-A in the inhibition of neurite outgrowth. The most
exciting frontier of reticulon research, however, is in the
field of neurodegenerative disease. There is growing
evidence that reticulons may have a role in amyotrophic
lateral sclerosis (ALS), Alzheimer’s disease, multiple sclerosis
and perhaps hereditary spastic paraplegia.
In 2004 it was found that all four human reticulon proteins
interact with the enzyme that produces the pathologic agent
in Alzheimer’s disease. He et al. [86] showed that BACE1,
the δ-secretase that cleaves amyloid precursor protein (APP)
into  β-amyloid peptide (Aβ), co-immunoprecipitates with
RTN1, RTN2, RTN3 and RTN4 [86]. In vitro, over-
expression of a single RTN reduced the levels of Aβ
produced by HEK-293 cells expressing the Swedish mutant
of APP, and conversely, knockdown of RTN3 by RNA
interference increased Aβ levels [54]. More recently,
Murayama and colleagues screened for proteins that interact
with BACE1 and identified RTN3 and RTN4 [87]. These
authors also demonstrated decreased Aβ production in cells
expressing the Swedish mutant [87]. Notably, in a
subtractive hybridization screen, Yokota and colleagues [88]
found that human RTN3 was downregulated in the temporal
lobes of Alzheimer’s patients. Although these data are
intriguing, the exact role of reticulons in Alzheimer’s disease
remains unknown, and further investigation is needed to
confirm whether these proteins may be potential therapeutic
targets in Alzheimer’s disease.
Reticulons have also been found to be involved in ALS. In
an ALS mouse model expressing human superoxide
dismutase (SOD) containing a disease-causing dominant
mutation, Dupuis et al. [89] found differential up- and
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with wild-type mice. Jokic et al. [90] demonstrated that
levels of RTN4 in muscle biopsies of ALS patients
correlated with disease severity. Pradat et al. [91] found
that expression of RTN4A in lower motor neuron
syndromes was prognostic of ALS, but Wojcik and
colleagues [92] have found recently that RTN4A
expression is not unique to ALS. Genetic analysis of RTN4
in the SOD mouse model of ALS shows that it has a
significant impact on survival [93]. Importantly, this effect
on survival does not seem to be due to a direct effect on
mutant SOD levels (YSY and SMS, unpublished data), and
may instead be related to the roles of RTN4A in vesicle
formation and trafficking. It is of note that RTN4A levels in
muscle increase in surgically denervated wild-type mice
[94], and as mentioned above, other groups have found
that changes in RTN4A expression are not necessarily
specific to ALS [92]. Considering the impact of RTN4 in
the mouse model of ALS, however, this protein remains a
possible candidate drug target for the disease.
Lastly, RTN4 may have a role in multiple sclerosis and
hereditary spastic paraplegia. Autoantibodies against the
isoform A-specific region of RTN4 have been found in serum
and cerebrospinal fluid of patients with multiple sclerosis
[95]. Interestingly, administration of exogenous anti-RTN4A
antibodies protects against demyelination in the experi-
mental autoimmune encephalitis mouse model of multiple
sclerosis [96]. Spastin, the most commonly mutated protein
in hereditary spastic paraplegia, was found to interact with
RTN1 and RTN3 via yeast two-hybrid screening; the inter-
action between spastin and RTN1 was further confirmed by
co-immunoprecipitation and co-localization of the two
proteins in transfected HeLa cells [97,98].
Questions remain regarding all aspects of the reticulon
family, from its most basic characteristics such as membrane
topology to its partners in intracellular trafficking, to the
downstream signaling molecules that effect the reticulons’
influence on human disease. Despite the lack of consensus
about the mechanism of action of reticulons in normal
cellular function and in neurodegenerative disease, their
involvement in several disease processes makes them
important targets for therapeutic development.
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Figure 4
Interaction of Nogo-A with Nogo receptor. The interaction of Nogo-A
(RTN4A) on oligodendrocytes and the Nogo receptor (NogoR) on
neurons results in inhibition of axon regeneration after injury via Rho
signaling [17,23,55,59,61-63,79]. The different regions of Nogo-A are
colored as follows: red, 66-loop (Nogo66); green, Nogo-A-24; blue, ∆20.
NogoR is in orange. The 66-loop interacts with NogoR to mediate
growth-cone collapse and neurite outgrowth in vitro and to inhibit axon
regeneration after injury [21,23,25,53,56,58,60,62]. The amino-terminal
region Nogo-A-24 increases the binding affinity of Nogo-A to NogoR and
also binds NogoR directly [15]. The amino-terminal region ∆20 can
mediate fibroblast and growth-cone collapse independently of NogoR
[16]. Some known co-receptors and signal transducers are listed beside
the yellow symbol and are described in more detail in Table 1.
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Table 1
Co-receptors and signal transducers in the Nogo-A-NogoR
interaction
Molecular 
region/
interactor Function/interaction Reference(s)
NogoA-24 Increases binding affinity of Nogo-A to  [15]
Nogo receptor (NogoR); binds NogoR 
directly
∆20 Mediates fibroblast and growth cone  [16]
collapse independently of NogoR 
p75NTR Neurotrophin receptor; binds NogoR  [72,73]
and mediates inhibition of neurite 
outgrowth via myelin-associated inhibitors
LINGO-1 Binds NogoR; activates Rho in complex  [74,75]
with p75 and NogoR; mediates 
Nogo66-induced neurite outgrowth 
inhibition
TAJ/TROY Binds NogoR, activates Rho in complex  [76,77]
with LINGO-1 and NogoR; absence 
attenuates myelin inhibition of neurite 
outgrowth
EGFR Kinase activity required for neurite  [78]
outgrowth but EGFR does not bind NogoRReferences
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